The most recent data indicates that Tirzepatide has demonstrated a mean AHI reduction of up to 63% (approximately 30 fewer events per hour), successfully meeting all primary and key secondary endpoints in two clinical trials
For women with Polycystic Ovary Syndrome, the metabolic mechanisms of tirzepatide are particularly relevant, as insulin resistance and appetite dysregulation are central features of the condition
A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M
Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, et al
A 37-amino acid long-acting acylated amylin analog that activates amylin and calcitonin receptors to modulate appetite signaling in homeostatic and hedonic brain regions, studied in clinical trials for weight management
Lactobacillus reuteri to treat infant colic: a meta-analysis